Phoenix Financial Ltd. Cuts Stake in Boston Scientific Corporation $BSX

Phoenix Financial Ltd. lowered its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 14.9% in the 4th quarter, HoldingsChannel.com reports. The firm owned 64,968 shares of the medical equipment provider’s stock after selling 11,340 shares during the period. Phoenix Financial Ltd.’s holdings in Boston Scientific were worth $6,194,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in BSX. Egerton Capital UK LLP grew its position in shares of Boston Scientific by 223.7% during the third quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock worth $518,660,000 after purchasing an additional 3,671,548 shares in the last quarter. Jennison Associates LLC grew its position in shares of Boston Scientific by 133.5% during the third quarter. Jennison Associates LLC now owns 4,938,746 shares of the medical equipment provider’s stock worth $482,170,000 after purchasing an additional 2,823,744 shares in the last quarter. Alphinity Investment Management Pty Ltd purchased a new stake in shares of Boston Scientific during the fourth quarter worth about $252,918,000. Marshall Wace LLP grew its position in shares of Boston Scientific by 30.7% during the third quarter. Marshall Wace LLP now owns 9,799,040 shares of the medical equipment provider’s stock worth $956,680,000 after purchasing an additional 2,301,383 shares in the last quarter. Finally, Credit Agricole S A purchased a new stake in shares of Boston Scientific during the third quarter worth about $204,812,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on BSX. Barclays cut their target price on Boston Scientific from $124.00 to $96.00 and set an “overweight” rating for the company in a research report on Thursday, April 23rd. UBS Group cut their price target on Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a report on Tuesday, March 17th. Daiwa Securities Group cut Boston Scientific from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Argus upgraded Boston Scientific to a “strong-buy” rating in a report on Thursday, February 26th. Finally, The Goldman Sachs Group cut their price target on Boston Scientific from $87.00 to $84.00 and set a “buy” rating for the company in a report on Wednesday, April 22nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $93.91.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific is being highlighted for strong international growth, with APAC momentum, FARAPULSE adoption, and new approvals in Europe and China helping expand its global footprint. Here’s How Boston Scientific Is Expanding Its Global Growth
• Positive Sentiment: Jim Cramer said he would “hold” BSX, implying he sees the company as a stock investors may want to keep rather than sell, which can help sentiment. Jim Cramer on Boston Scientific: “I Think You Gotta Hold It”
• Positive Sentiment: Recent commentary continues to point to Boston Scientific’s cardiovascular franchise as a long-term growth driver, with products like FARAPULSE and WATCHMAN supporting demand. Should You Buy, Hold or Sell BSX Stock Amid Cardiovascular Boom?
• Neutral Sentiment: The company treated its first patient with Seismiq IVL in the ELEGANCE registry, a small but positive clinical/commercial update that adds to its product pipeline narrative. Boston Scientific treats first patient with Seismiq IVL in ELEGANCE registry
• Neutral Sentiment: Boston Scientific filed a shelf registration tied to an ESOP-related offering and approved governance changes, which may help align incentives but also adds dilution/watch-list considerations for investors. Is Boston Scientific (BSX) Quietly Recasting Its Ownership Structure To Sharpen Its Investment Story?
• Negative Sentiment: Some reports say BSX has fallen amid concerns that its growth may not be durable, which likely weighed on sentiment. Boston Scientific (BSX) Fell Amid Concerns Over Growth Durability
• Negative Sentiment: Insiders reportedly sold about $1.2 million of shares, which can signal caution and add to investor concern during a weak stretch for the stock. Boston Scientific Insiders Sold US$1.2m Of Shares Suggesting Hesitancy
• Negative Sentiment: MarketWatch noted that Boston Scientific underperformed peers, reinforcing the view that investor sentiment remains cautious despite the company’s long-term growth story. Boston Scientific Corp. stock underperforms Wednesday when compared to competitors

Boston Scientific Stock Performance

NYSE BSX opened at $53.61 on Friday. The stock has a market capitalization of $79.67 billion, a PE ratio of 22.43, a P/E/G ratio of 0.97 and a beta of 0.62. The business has a 50 day simple moving average of $63.79 and a two-hundred day simple moving average of $82.00. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. Boston Scientific Corporation has a 1-year low of $52.75 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same period last year, the company earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, research analysts predict that Boston Scientific Corporation will post 3.38 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.